Deal Library / Pharma BD Deal Intelligence

Incyte Corporation — Pharma Deals

The Pharma Closeout tracks 7 deals, $8.5B in disclosed deal value, 4 with a post-close Outcome Score for Incyte Corporation.

Median Critic Score: 64  ·  Median Outcome Score: 64

Best outcome: Incyte Corporation / MacroGenics, Inc. (69)  ·  Weakest outcome: Incyte Corporation / Merus N.V. (35)

All 7 deals

• Incyte Corporation / MacroGenics, Inc. — 2017 · $900M · Largely worked — most objectives met.
• Incyte Corporation / Vega Therapeutics, Inc. — 2026 · $2.0B · Largely worked — most objectives met.
• Incyte Corporation / Halozyme Therapeutics, Inc. — 2026 · Largely worked — most objectives met.
• Incyte Corporation / Merus N.V. — 2017 · $3.0B · Underwhelmed — fell short of the thesis.
• Incyte Corporation / Genesis Molecular AI, Inc. — 2026 · $1.0B
• Incyte Corporation / Escient Pharmaceuticals Inc. — 2024 · $750M
• Incyte Corporation / Calithera Biosciences, Inc. — 2017 · $803M

← Deal Library  ·  Interactive search  ·  How we score deals